

Red Chip Interview with Immuron Vice Chairman

8 September 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) is pleased to make available Red Chip Group Companies Inc. (Red Chip)'s recent interview with Immuron Vice Chairman Peter Anastasiou.

During the interview with Red Chip's President and CEO Dave Gentry, Mr. Anastasiou explains Immuron's current product offerings, the status of the NASH and ASH Phase II clinical trials, and the Company's value proposition and expansion plans for the US market.

The interview can be viewed on the Immuron website at: www.immuron.com.

As previously announced, Immuron engaged Red Chip for the provision of certain US Investor Relations Services. On 20th August Red Chip released an Analyst Report which attracted significant online and market attention. A copy of this report is available at www.immuron.com/index.php/download file/-/view/140/.

The Board of Immuron sees the US Market as being an exciting opportunity to expand and diversify Immuron's product sales and shareholder investment base as the US market continues to recognise the value-opportunity of Australian biotechnology companies to that of their US biotechnology peers.

Contact:

Dr Roger Aston Non-Executive Chairman Ph:+61 (0)3 9824 5254 Mr Peter Anastasiou Vice Chairman Ph:+61 (0)419 511 604

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers' diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron's main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).